# Variant Analysis Report  ver1 

**Gene:** TP53

**Variant:** c.818G>A

---

<think>
Okay, let's tackle this variant interpretation for TP53 c.818G>A (p.Arg273His). First, I need to recall the ACMG/AMP 2015 guidelines and the ClinGen SVI recommendations. The user provided all the necessary data, so I should go through each criterion step by step.

Starting with PVS1: This is for variants in a gene where the variant is a null (nonsense, frameshift, splice site) and the gene is known to be haploinsufficient. TP53 is definitely haploinsufficient, but this is a missense variant, not a null. So PVS1 doesn't apply here.

Next, PS1-4. PS1 is for a variant in a well-established functional domain with a strong effect. The p.Arg273His is in the DNA-binding domain of TP53. Arg273 is a critical residue, and His substitution might disrupt DNA binding. The in vitro data shows loss of transactivation activity, which supports PS1. So PS1 is likely applicable.

PS2 is for a variant that is absent in controls. The gnomAD AF is 0.000008, which is very low, so PS2 applies. PS3 is for segregation data, but the user said family segregation is N/A, so PS3 doesn't apply. PS4 is for population data, but since the AF is extremely low, maybe PS4 is not needed here. Wait, PS4 is for population data showing a significant difference between cases and controls. Since the AF is so low, maybe PS4 isn't applicable unless there's case-control data, which isn't provided. So PS4 might not be applicable here.

PM1-6: PM1 is for a variant in a region of the gene that is known to be pathogenic. The DNA-binding domain is a known pathogenic region, so PM1 applies. PM2 is for a variant that is predicted to affect protein function. The in vitro data shows loss of transactivation, so PM2 applies. PM3 is for a variant that is in a region of the gene that is known to be pathogenic, which overlaps with PM1. PM4 is for a variant that is predicted to be damaging by computational tools. CADD 28.5 and REVEL 0.95 are both high, so PM4 applies. PM5 is for a variant that is in a region of the gene that is known to be pathogenic, which again overlaps with PM1. PM6 is for a variant that is in a region of the gene that is known to be pathogenic, which again overlaps. So PM1, PM2, PM4, PM5, PM6 might all apply, but need to check if they are distinct criteria.

PP1-5: PP1 is for a variant that is found in a case with a known phenotype. The user didn't mention the patient's phenotype, so maybe not applicable. PP2 is for a variant that is in a gene where the variant is known to be pathogenic. TP53 is a well-known tumor suppressor gene, so PP2 applies. PP3 is for functional studies supporting pathogenicity. The in vitro data shows loss of transactivation, so PP3 applies. PP4 is for a variant that is in a region of the gene that is known to be pathogenic, which again overlaps with PM1. PP5 is for a variant that is in a region of the gene that is known to be pathogenic, which again overlaps. So PP2 and PP3 are applicable.

BA1: This is for a variant that is a known pathogenic variant in the same gene. ClinVar lists it as pathogenic, so BA1 applies.

BS1-4: BS1 is for a variant that is found in controls. The gnomAD AF is very low, so BS1 doesn't apply. BS2 is for a variant that is predicted to be benign by computational tools. CADD and REVEL are high, so BS2 doesn't apply. BS3 is for a variant that is in a region of the gene that is known to be benign. Since the region is pathogenic, BS3 doesn't apply. BS4 is for a variant that is in a region of the gene that is known to be benign, which again doesn't apply.

BP1-7: BP1 is for a variant that is in a region of the gene that is known to be benign. Since the region is pathogenic, BP1 doesn't apply. BP2 is for a variant that is predicted to be benign by computational tools. CADD and REVEL are high, so BP2 doesn't apply. BP3 is for a variant that is in a region of the gene that is known to be benign. Again, no. BP4 is for a variant that is in a region of the gene that is known to be benign. No. BP5 is for a variant that is in a region of the gene that is known to be benign. No. BP6 is for a variant that is in a region of the gene that is known to be benign. No. BP7 is for a variant that is in a region of the gene that is known to be benign. No.

Now, applying ClinGen SVI for PS3/BS3 and PVS1. Since PS3 is not applicable (no segregation data), and PVS1 doesn't apply (not a null variant), but the variant is in a critical domain with strong functional evidence.

Putting it all together: The variant has strong evidence from PS1, PS2, PM1, PM2, PM4, PM5, PM6, PP2, PP3, and BA1. The only possible conflicting evidence is if there's any, but the gnomAD AF is extremely low, so no BS1. The final classification would be Pathogenic, as per the criteria.
</think>

### **ACMG/AMP 2015 기준에 따른 변이 해석**

#### **1. PVS1 (Pathogenic Variant in a Gene with Haploinsufficiency)**
- **적용 여부**: **불적용**
- **근거**:  
  - TP53은 haploinsufficiency 유전자로 분류되지만, 이 변이는 **missense** 유형이며, **null variant**가 아닙니다.  
  - PVS1은 **nonsense, frameshift, splice site** 등 null 유형의 변이에만 적용됩니다.

---

#### **2. PS1-PS4 (Strong Evidence for Pathogenicity)**
- **PS1 (Well-established Functional Domain with Strong Effect)**  
  - **적용 여부**: **적용**  
  - **근거**:  
    - **p.Arg273His**는 TP53의 **DNA-binding domain**에 위치하며, 이 영역은 TP53의 기능에 필수적입니다.  
    - **In vitro 데이터**에서 **transactivation activity의 손실**이 확인되었으며, 이는 기능적 손상의 강력한 증거입니다.  
    - ClinGen SVI 권고안에 따라, **PS3 (Segregation Data)**는 **불적용** (가계 분리 데이터 없음), **PVS1 강도 조절**도 불적용입니다.

- **PS2 (Absent in Controls)**  
  - **적용 여부**: **적용**  
  - **근거**:  
    - **gnomAD AF (전체)**: 0.000008 (극히 낮은 빈도).  
    - **gnomAD popmax**: Unknown, **동형접합**: Unknown.  
    - 이는 일반 인구에서의 빈도가 극히 낮아 **PS2** 기준을 충족합니다.

- **PS3 (Segregation Data)**  
  - **적용 여부**: **불적용**  
  - **근거**:  
    - 가계 분리 데이터가 제공되지 않았습니다.

- **PS4 (Population Data)**  
  - **적용 여부**: **불적용**  
  - **근거**:  
    - 환자-대조군 연구 데이터가 없으며, **gnomAD** 데이터만으로는 **PS4** 기준을 충족하지 못합니다.

---

#### **3. PM1-PM6 (Moderate Evidence for Pathogenicity)**
- **PM1 (Known Pathogenic Region)**  
  - **적용 여부**: **적용**  
  - **근거**:  
    - **p.Arg273His**는 TP53의 **DNA-binding domain**에 위치하며, 이 영역은 **pathogenic variants**가 집중된 영역입니다.

- **PM2 (Functional Studies)**  
  - **적용 여부**: **적용**  
  - **근거**:  
    - **In vitro** 실험에서 **transactivation activity의 손실**이 확인되었습니다.

- **PM3 (Population Data)**  
  - **적용 여부**: **불적용**  
  - **근거**:  
    - **gnomAD** 데이터는 **PS2**에 이미 적용되었으며, **PM3**는 **case-control study** 데이터가 필요합니다.

- **PM4 (Computational Prediction)**  
  - **적용 여부**: **적용**  
  - **근거**:  
    - **CADD**: 28.5 (높은 손상 예측), **REVEL**: 0.95 (높은 병원성 예측).  
    - **SpliceAI**: N/A, **phyloP**: N/A (보존성 데이터 없음).

- **PM5 (Known Pathogenic Variant in the Same Gene)**  
  - **적용 여부**: **적용**  
  - **근거**:  
    - **ClinVar**에서 **Pathogenic**으로 분류되어 있습니다.

- **PM6 (Known Pathogenic Variant in the Same Amino Acid Position)**  
  - **적용 여부**: **적용**  
  - **근거**:  
    - **p.Arg273His**는 TP53의 **Arg273** 위치에서의 변이로, 이 위치는 **pathogenic variants**가 집중된 것으로 알려져 있습니다.

---

#### **4. PP1-PP5 (Supporting Evidence for Pathogenicity)**
- **PP1 (Case with Known Phenotype)**  
  - **적용 여부**: **불적용**  
  - **근거**:  
    - 환자의 임상 증상 데이터가 제공되지 않았습니다.

- **PP2 (Gene with Well-Established Pathogenicity)**  
  - **적용 여부**: **적용**  
  - **근거**:  
    - **TP53**은 **tumor suppressor gene**으로, **Li-Fraumeni syndrome**과 관련된 유전자로 잘 알려져 있습니다.

- **PP3 (Functional Studies Supporting Pathogenicity)**  
  - **적용 여부**: **적용**  
  - **근거**:  
    - **In vitro** 실험에서 **transactivation activity의 손실**이 확인되었습니다.

- **PP4 (Known Pathogenic Variant in the Same Gene)**  
  - **적용 여부**: **적용**  
  - **근거**:  
    - **ClinVar**에서 **Pathogenic**으로 분류되어 있습니다.

- **PP5 (Known Pathogenic Variant in the Same Amino Acid Position)**  
  - **적용 여부**: **적용**  
  - **근거**:  
    - **p.Arg273His**는 **TP53**의 **Arg273** 위치에서의 변이로, 이 위치는 **pathogenic variants**가 집중된 것으로 알려져 있습니다.

---

#### **5. BA1 (Known Pathogenic Variant in the Same Gene)**  
- **적용 여부**: **적용**  
- **근거**:  
  - **ClinVar**에서 **Pathogenic**으로 분류되어 있습니다.

---

#### **6. BS1-BS4 (Evidence Against Pathogenicity)**
- **BS1 (Present in Controls)**  
  - **적용 여부**: **불적용**  
  - **근거**:  
    - **gnomAD AF**가 극히 낮아 **BS1** 기준을 충족하지 않습니다.

- **BS2 (Computational Prediction of Benign)**  
  - **적용 여부**: **불적용**  
  - **근거**:  
    - **CADD**와 **REVEL**은 **높은 병원성 예측**을 보입니다.

- **BS3 (Known Benign Variant in the Same Gene)**  
  - **적용 여부**: **불적용**  
  - **근거**:  
    - **TP53**의 **Arg273** 위치는 **pathogenic variants**가 집중된 것으로 알려져 있습니다.

- **BS4 (Known Benign Variant in the Same Amino Acid Position)**  
  - **적용 여부**: **불적용**  
  - **근거**:  
    - **p.Arg273His**는 **pathogenic variants**가 집중된 위치입니다.

---

#### **7. BP1-BP7 (Evidence Against Pathogenicity)**
- **BP1-BP7**: **모두 불적용**  
- **근거**:  
  - **TP53**의 **Arg273** 위치는 **pathogenic variants**가 집중된 것으로 알려져 있으며, **computational prediction**과 **functional studies** 모두 병원성을 지지합니다.

---

### **최종 분류 및 신뢰도**
- **분류**: **Pathogenic**  
- **신뢰도**: **고도로 신뢰할 수 있음**  
- **임상적 해석**:  
  - **TP53 c.818G>A (p.Arg273His)**는 **DNA-binding domain**에 위치한 **missense** 변이로, **in vitro** 실험에서 **transactivation activity의 손실**이 확인되었습니다.  
  - **gnomAD**에서 극히 낮은 빈도를 보이며, **ClinVar**에서 **Pathogenic**으로 분류되어 있습니다.  
  - **CADD**와 **REVEL**은 **높은 병원성 예측**을 보이며, **TP53**은 **haploinsufficiency 유전자**로 잘 알려져 있습니다.  
  - **ACMG/AMP 2015 기준**에 따라 **PS1, PS2, PM1, PM2, PM4, PM5, PM6, PP2, PP3, BA1** 등 **강력한 병원성 증거**가 충족되었습니다.  
  - **ClinGen SVI 권고안**에 따라 **PVS1 강도 조절**은 불적용이며, **PS3**도 불적용입니다.  

**결론**: 이 변이는 **TP53**의 **Li-Fraumeni syndrome**과 관련된 **병원성 변이**로 분류됩니다.